The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Open accessAbstract
Antibodies and Fc-fusion antibody-like proteins have become successful biologics developed for cancer treatment, passive immunity against infection, addiction, and autoimmune diseases. In general these biopharmaceuticals can be used for blocking protein:protein interactions, crosslinking host receptors to induce signaling, recruiting effector cells to targets, and fixing complement. With the vast capability of antibodies to affect infectious and genetic diseases much effort has been placed on improving and tailoring antibodies for specific functions. While antibody:antigen engagement is critical for an efficacious antibody biologic, equally as important are the hinge and constant domains of the heavy chain. It is the hinge and constant domains of the antibody that engage host receptors or complement protein to mediate a myriad of effector functions and regulate antibody circulation. Molecular and structural studies have provided insight into how the hinge and constant domains from antibodies across different species, isotypes, subclasses, and alleles are recognized by host cell receptors and complement protein C1q. The molecular details of these interactions have led to manipulation of the sequences and glycosylation of hinge and constant domains to enhance or reduce antibody effector functions and circulating half-life. This review will describe the concepts being applied to optimize the hinge and crystallizable fragment of antibodies, and it will detail how these interactions can be tuned up or down to mediate a biological function that confers a desired disease outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,286
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Innate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer
Karin, M., Lawrence, T., & Nizet, V. (2006) · Cell · doi:10.1016/j.cell.2006.02.016 · Cited by 942
Nisonoff, A., Wissler, F. C., Lipman, L. N., & Woernley, D. L. (1960) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(60)90049-7 · Cited by 936
Fc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
Anatomy of the antibody molecule
Padlan, E. A. (1994) · Molecular Immunology · doi:10.1016/0161-5890(94)90001-9 · Cited by 896
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 796
Koene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 23×
“To silence the effector functions of Fc, large portions of Fc regions from different subclasses have been exchanged to generate crosssubclass Fc regions (141).”
BackgroundInfluentialFerrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Monoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C. J., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 733
The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 719
Tumor-Associated Neutrophils: New Targets for Cancer Therapy
Gregory, A. D., & McGarry Houghton, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2583 · Cited by 707
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
A complete immunoglobulin gene is created by somatic recombination
Brack, C., Hirama, M., Lenhard-Schuller, R., & Tonegawa, S. (1978) · Cell · doi:10.1016/0092-8674(78)90078-8 · Cited by 610
Brüggemann, M., Williams, G. T., Bindon, C. I., Clark, M. R., Walker, M. R., Jefferis, R., Waldmann, H., & Neuberger, M. S. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.5.1351 · Cited by 607
A 13-amino-acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling
Muta, T., Kurosaki, T., Misulovin, Z., Sanchez, M., Nussenzweig, M. C., & Ravetch, J. V. (1994) · Nature · doi:10.1038/368070a0 · Cited by 580
The binding site for C1q on IgG
Duncan, A. R., & Winter, G. (1988) · Nature · doi:10.1038/332738a0 · Cited by 569
Tao, M. H., & Morrison, S. L. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.8.2595 · Cited by 530
Metabolic properties of IgG subclasses in man
Morell, A., Terry, W. D., & Waldmann, T. A. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106279 · Cited by 526
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Mendoza, P., Gruell, H., Nogueira, L., Pai, J. A., Butler, A. L., Millard, K., Lehmann, C., Suárez, I., Oliveira, T. Y., Lorenzi, J. C. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0531-2 · Cited by 521
Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Bournazos, S., Klein, F., Pietzsch, J., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2014) · Cell · doi:10.1016/j.cell.2014.08.023 · Cited by 493
Cytoplasmic Domain Heterogeneity and Functions of IgG Fc Receptors in B Lymphocytes
Amigorena, S., Bonnerot, C., Drake, J. R., Choquet, D., Hunziker, W., Guillet, J.-G., Webster, P., Sautes, C., Mellman, I., & Fridman, W. H. (1992) · Science · doi:10.1126/science.1535455 · Cited by 455
Kaplon, H., & Reichert, J. M. (2019) · mAbs · doi:10.1080/19420862.2018.1556465 · Cited by 434
Crystal structure of the complex of rat neonatal Fc receptor with Fc
Burmeister, W. P., Huber, A. H., & Bjorkman, P. J. (1994) · Nature · doi:10.1038/372379a0 · Cited by 431
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428 · cited 3×
“Since both heavy chains are glycosylated it is possible for a single IgG molecule to have significant glycan heterogeneity (71).”
BackgroundSchlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw040 · Cited by 425
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
Crystallographic structure studies of an IgG molecule and an Fc fragment
Huber, R., Deisenhofer, J., Colman, P. M., Matsushima, M., & Palm, W. (1976) · Nature · doi:10.1038/264415a0 · Cited by 422
Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex
Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391
The molecular basis of antibody formation: a paradox.
Dreyer, W. J., & Bennett, J. C. (1965) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.54.3.864 · Cited by 390
Human antibody–Fc receptor interactions illuminated by crystal structures
Woof, J. M., & Burton, D. R. (2004) · Nature Reviews Immunology · doi:10.1038/nri1266 · Cited by 387
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Ko, S.-Y., Pegu, A., Rudicell, R. S., Yang, Z.-Y., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Rath, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 384
Self-citationCrystal structure of the complex of rat neonatal Fc receptor with Fc
(1995) · Trends in Genetics · doi:10.1016/0168-9525(95)90005-5 · Cited by 381
Three-dimensional structure of an intact human immunoglobulin.
Silverton, E. W., Navia, M. A., & Davies, D. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.11.5140 · Cited by 375
Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372
Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences
Acqua, W. F. D., Woods, R. M., Ward, E. S., Palaszynski, S. R., Patel, N. K., Brewah, Y. A., Wu, H., Kiener, P. A., & Langermann, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5171 · Cited by 368
Robbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Dekkers, G., Treffers, L., Plomp, R., Bentlage, A. E. H., de Boer, M., Koeleman, C. A. M., Lissenberg-Thunnissen, S. N., Visser, R., Brouwer, M., Mok, J. Y., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00877 · Cited by 356
The Carbohydrate at FcγRIIIa Asn-162
Ferrara, C., Stuart, F., Sondermann, P., Brünker, P., & Umaña, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510171200 · Cited by 354
Mimura, Y., Church, S., Ghirlando, R., Ashton, P. R., Dong, S., Goodall, M., Lund, J., & Jefferis, R. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00105-x · Cited by 329
Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1119 · Cited by 327
Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
Lo, M., Kim, H. S., Tong, R. K., Bainbridge, T. W., Vernes, J.-M., Zhang, Y., Lin, Y. L., Chung, S., Dennis, M. S., Zuchero, Y. J. Y., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767749 · Cited by 323
Raghavan, M., Bonagura, V. R., Morrison, S. L., & Bjorkman, P. J. (1995) · Biochemistry · doi:10.1021/bi00045a005 · Cited by 317
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn
Ober, R. J., Martinez, C., Vaccaro, C., Zhou, J., & Ward, E. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2021 · Cited by 314
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
Richards, J. O., Karki, S., Lazar, G. A., Chen, H., Dang, W., & Desjarlais, J. R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0201 · Cited by 313
Mouse model recapitulating human Fcγ receptor structural and functional diversity
Smith, P., DiLillo, D. J., Bournazos, S., Li, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203954109 · Cited by 307
Hezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. J., & Parren, P. W. H. I. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12161-12168.2001 · Cited by 294
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Stapleton, N. M., Andersen, J. T., Stemerding, A. M., Bjarnarson, S. P., Verheul, R. C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., et al. (2011) · Nature Communications · doi:10.1038/ncomms1608 · Cited by 286
Stavenhagen, J. B., Gorlatov, S., Tuaillon, N., Rankin, C. T., Li, H., Burke, S., Huang, L., Johnson, S., Bonvini, E., & Koenig, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0696 · Cited by 284
Horton, H. M., Bernett, M. J., Pong, E., Peipp, M., Karki, S., Chu, S. Y., Richards, J. O., Vostiar, I., Joyce, P. F., Repp, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2268 · Cited by 272
Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity
Quast, I., Keller, C. W., Maurer, M. A., Giddens, J. P., Tackenberg, B., Wang, L.-X., Münz, C., Nimmerjahn, F., Dalakas, M. C., & Lünemann, J. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82695 · Cited by 269
Moore, G. L., Chen, H., Karki, S., & Lazar, G. A. (2010) · mAbs · doi:10.4161/mabs.2.2.11158 · Cited by 266
Selective IgG subclass deficiency: quantification and clinical relevance
JEFFERIS, R., & KUMARARATNE, D. S. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb05339.x · Cited by 265
pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat.
Rodewald, R. (1976) · The Journal of cell biology · doi:10.1083/jcb.71.2.666 · Cited by 264
Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259
IgG2 subclass restriction of antibody to pneumococcal polysaccharides.
Barrett, D. J., & Ayoub, E. M. (1986) · PubMed · Cited by 259
West, A. P., & Bjorkman, P. J. (2000) · Biochemistry · doi:10.1021/bi000749m · Cited by 257
Nordstrom, J. L., Gorlatov, S., Zhang, W., Yang, Y., Huang, L., Burke, S., Li, H., Ciccarone, V., Zhang, T., Stavenhagen, J., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3069 · Cited by 250
Molecular engineering and design of therapeutic antibodies
Presta, L. G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.012 · Cited by 250
Structure and activation of the C1 complex of complement: unraveling the puzzle
Gaboriaud, C., Thielens, N. M., Gregory, L. A., Rossi, V., Fontecilla-Camps, J. C., & Arlaud, G. J. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.04.008 · Cited by 247
Ishii, T., Ishida, T., Utsunomiya, A., Inagaki, A., Yano, H., Komatsu, H., Iida, S., Imada, K., Uchiyama, T., Akinaga, S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2697 · Cited by 246
Reichert, J. M. (2017) · mAbs · doi:10.1080/19420862.2016.1269580 · Cited by 244
Increasing the serum persistence of an IgG fragment by random mutagenesis
Ghetie, V., Popov, S., Borvak, J., Radu, C., Matesoi, D., Medesan, C., Ober, R. J., & Ward, E. S. (1997) · Nature Biotechnology · doi:10.1038/nbt0797-637 · Cited by 241
In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies
Xu, D., Alegre, M.-L., Varga, S. S., Rothermel, A. L., Collins, A. M., Pulito, V. L., Hanna, L. S., Dolan, K. P., Parren, P. W. H. I., Bluestone, J. A., et al. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1617 · Cited by 238
Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding
Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S. P., Goodall, M., & Jefferis, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107478200 · Cited by 236
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
Sockolosky, J. T., & Szoka, F. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.005 · Cited by 235
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
Caskey, M., Klein, F., & Nussenzweig, M. C. (2019) · Nature Medicine · doi:10.1038/s41591-019-0412-8 · Cited by 229
Niwa, R., Hatanaka, S., Shoji-Hosaka, E., Sakurada, M., Kobayashi, Y., Uehara, A., Yokoi, H., Nakamura, K., & Shitara, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0850 · Cited by 227
Bang, Y. J., Giaccone, G., Im, S. A., Oh, D. Y., Bauer, T. M., Nordstrom, J. L., Li, H., Chichili, G. R., Moore, P. A., Hong, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx002 · Cited by 226
Peschke, B., Keller, C. W., Weber, P., Quast, I., & Lünemann, J. D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00646 · Cited by 219
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Uppal, H., Doudement, E., Mahapatra, K., Darbonne, W. C., Bumbaca, D., Shen, B.-Q., Du, X., Saad, O., Bowles, K., Olsen, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2093 · Cited by 218
The three-dimensional structure of an intact monoclonal antibody for canine lymphoma
Harris, L. J., Larson, S. B., Hasel, K. W., Day, J., Greenwood, A., & McPherson, A. (1992) · Nature · doi:10.1038/360369a0 · Cited by 217
Lund, J., Takahashi, N., Pound, J. D., Goodall, M., & Jefferis, R. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4963 · Cited by 216
Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG
Lund, J., Winter, G., Jones, P. T., Pound, J. D., Tanaka, T., Walker, M. R., Artymiuk, P. J., Arata, Y., Burton, D. R., Jefferis, R., et al. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.8.2657 · Cited by 212
Marketing approval of mogamulizumab: A triumph for glyco-engineering
Beck, A., & Reichert, J. M. (2012) · mAbs · doi:10.4161/mabs.20996 · Cited by 211
Identity of the elusive IgM Fc receptor (FcμR) in humans
Kubagawa, H., Oka, S., Kubagawa, Y., Torii, I., Takayama, E., Kang, D.-W., Gartland, G. L., Bertoli, L. F., Mori, H., Takatsu, H., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20091107 · Cited by 209
Yamaguchi, Y., Nishimura, M., Nagano, M., Yagi, H., Sasakawa, H., Uchida, K., Shitara, K., & Kato, K. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.10.002 · Cited by 204
Structural characterization of a human Fc fragment engineered for lack of effector functions
Oganesyan, V., Gao, C., Shirinian, L., Wu, H., & Dall'Acqua, W. F. (2008) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444908007877 · Cited by 197
Structural and functional anatomy of the globular domain of complement protein C1q
Kishore, U., Ghai, R., Greenhough, T. J., Shrive, A. K., Bonifati, D. M., Gadjeva, M. G., Waters, P., Kojouharova, M. S., Chakraborty, T., & Agrawal, A. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.06.015 · Cited by 195
Wright, A., & Morrison, S. L. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.3.1087 · Cited by 192
Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6297 · Cited by 187
Wada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186
Vafa, O., Gilliland, G. L., Brezski, R. J., Strake, B., Wilkinson, T., Lacy, E. R., Scallon, B. J., Teplyakov, A., Malia, T., & Strohl, W. R. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.035 · Cited by 168
Optimization of Fc-mediated effector functions of monoclonal antibodies
Strohl, W. R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.011 · Cited by 168
Wright, A., & Morrison, S. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3393 · Cited by 158
Revisiting the Role of Glycosylation in the Structure of Human IgG Fc
Borrok, M. J., Jung, S. T., Kang, T. H., Monzingo, A. F., & Georgiou, G. (2012) · ACS Chemical Biology · doi:10.1021/cb300130k · Cited by 158
Griffin, M. P., Khan, A. A., Esser, M. T., Jensen, K. M., Takas, T., Kankam, M. K., Villafana, T. L., & Dubovsky, F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01714-16 · Cited by 156
Wines, B. D., Powell, M. S., Parren, P. W. H. I., Barnes, N. C., & Hogarth, P. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5313 · Cited by 152
Yu, X., Robbie, G. J., Wu, Y., Esser, M. T., Jensen, K. M., Schwartz, H. I., Bellamy, T., Hernandez‐Illas, M., & Jafri, H. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01020-16 · Cited by 147
Huck, S., Fort, P., Crawford, D., Lefranc, M., & Lefranc, G. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.4.1779 · Cited by 146
Ito, A., Ishida, T., Yano, H., Inagaki, A., Suzuki, S., Sato, F., Takino, H., Mori, F., Ri, M., Kusumoto, S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0632-0 · Cited by 142
Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region
Dall’Acqua, W. F., Cook, K. E., Damschroder, M. M., Woods, R. M., & Wu, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1129 · Cited by 138
Mimoto, F., Katada, H., Kadono, S., Igawa, T., Kuramochi, T., Muraoka, M., Wada, Y., Haraya, K., Miyazaki, T., & Hattori, K. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt022 · Cited by 136
Reaction between the isolated globular sub-units of the complement component Clq and IgG-complexes
Hughes-Jones, N. C., & Gardner, B. (1979) · Molecular Immunology · doi:10.1016/0161-5890(79)90010-5 · Cited by 135
Gura, T. (2002) · Nature · doi:10.1038/417584a · Cited by 131
Lund, J., Tanaka, T., Noriko, T., Sármay, G., Arata, Y., & Jefferis, R. (1990) · Molecular Immunology · doi:10.1016/0161-5890(90)90103-7 · Cited by 129
Gautam, R., Nishimura, Y., Gaughan, N. A., Gazumyan, A., Schoofs, T., Buckler-White, A. J., Seaman, M. S., Swihart, B., Follmann, D. A., Nussenzweig, M. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0001-2 · Cited by 121
Alegre, M. L. S., Collins, A., Pulito, V. L., Brosius, R., Olson, W. C., Zivin, R. A., Knowles, R. W., Thistlethwaite, J. R., Jolliffe, L. K., & Bluestone, J. A. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.11.3461 · Cited by 116
Saunders, K. O., Pegu, A., Georgiev, I. S., Zeng, M., Joyce, M. G., Yang, Z., Ko, S., Chen, X., Schmidt, S. D., Haase, A. T., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00210-15 · Cited by 111
Self-citationSármay, G., Lund, J., Rozsnyay, Z., Gergely, J., & Jefferis, R. (1992) · Molecular Immunology · doi:10.1016/0161-5890(92)90200-h · Cited by 109
Glycobiology: 'the function of sugar in the IgG molecule'.
Dwek, R. A., Lellouch, A. C., & Wormald, M. R. (1995) · PubMed · Cited by 107
IgG2m4, an engineered antibody isotype with reduced Fc function
An, Z., Forrest, G., Moore, R., Cukan, M. C., Haytko, P., Huang, L., Vitelli, S., Zhao, J. Z., Lü, P., Hua, J., et al. (2009) · mAbs · doi:10.4161/mabs.1.6.10185 · Cited by 104
Muta, T., Kurosaki, T., Misulovin, Z., Sanchez, M., Nussenzweig, M. C., & Ravetch, J. V. (1994) · Nature · doi:10.1038/369340a0 · Cited by 101
Romain, G., Senyukov, V., Rey-Villamizar, N., Merouane, A., Kelton, W., Liadi, I., Mahendra, A., Charab, W., Georgiou, G., Roysam, B., et al. (2014) · Blood · doi:10.1182/blood-2014-04-569061 · Cited by 98
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
McDonagh, C. F., Kim, K. M., Turcott, E., Brown, L. L., Westendorf, L., Feist, T., Sussman, D. R., Stone, I. J., Anderson, M. E., Miyamoto, J. B., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0295 · Cited by 95
Engineering Antibodies for Therapy
Presta, L. G. (2002) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023378256 · Cited by 94
Structural characterization of a mutated, ADCC-enhanced human Fc fragment
Oganesyan, V., Damschroder, M. M., Leach, W., Wu, H., & Dall’Acqua, W. F. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2007.10.042 · Cited by 89
Structure of the Murine Unglycosylated IgG1 Fc Fragment
Feige, M. J., Nath, S., Catharino, S., Weinfurtner, D., Steinbacher, S., & Büchner, J. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.06.048 · Cited by 89
Rankin, C. T., Verı́, M.-C., Gorlatov, S. N., Tuaillon, N., Burke, S., Huang, L., Inzunza, H. D., Li, H., Thomas, S., Johnson, S., et al. (2006) · Blood · doi:10.1182/blood-2006-05-020602 · Cited by 88
Immunoglobulin isotype knowledge and application to Fc engineering
Brezski, R. J., & Georgiou, G. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.002 · Cited by 86
Polymeric human Fc-fusion proteins with modified effector functions
Mekhaiel, D. N. A., Czajkowsky, D. M., Andersen, J. T., Shi, J., El-Faham, M., Doenhoff, M., McIntosh, R. S., Sandlie, I., He, J., Hu, J., et al. (2011) · Scientific Reports · doi:10.1038/srep00124 · Cited by 85
Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800896 · Cited by 82
Myeloid cells as effector cells for monoclonal antibody therapy of cancer
Braster, R., O’Toole, T. G., & van Egmond, M. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.020 · Cited by 82
Arduin, E., Arora, S., Bamert, P. R., Kuiper, T., Popp, S. L., Geisse, S., Grau, R., Calzascia, T., Zenke, G., & Kovařík, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.09.017 · Cited by 79
Kelton, W., Mehta, N., Charab, W., Lee, J., Lee, C., Kojima, T., Kang, T. H., & Georgiou, G. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.10.017 · Cited by 79
Mimoto, F., Igawa, T., Kuramochi, T., Katada, H., Kadono, S., Kamikawa, T., Shida-Kawazoe, M., & Hattori, K. (2013) · mAbs · doi:10.4161/mabs.23452 · Cited by 79
Aoyama, M., Hashii, N., Tsukimura, W., Osumi, K., Harazono, A., Tada, M., Kiyoshi, M., Matsuda, A., & Ishii‐Watabe, A. (2019) · mAbs · doi:10.1080/19420862.2019.1608143 · Cited by 79
Jung, S. T., Kelton, W., Kang, T. H., Ng, D. T. W., Andersen, J. T., Sandlie, I., Sarkar, C. A., & Georgiou, G. (2012) · ACS Chemical Biology · doi:10.1021/cb300455f · Cited by 75
Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa
Ahmed, A. A., Keremane, S., Vielmetter, J., & Björkman, P. J. (2016) · Journal of Structural Biology · doi:10.1016/j.jsb.2016.02.001 · Cited by 75
Borrok, M. J., Luheshi, N., Beyaz, N., Davies, G. C., Legg, J. W., Wu, H., Dall’Acqua, W. F., & Tsui, P. (2015) · mAbs · doi:10.1080/19420862.2015.1047570 · Cited by 73
Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation
Thommesen, J. E., Michaelsen, T. E., Løset, G. Å., Sandlie, I., & Brekke, O. H. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(01)00010-4 · Cited by 71
Xu, Y., Oomen, R. P., & Klein, M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41886-2 · Cited by 69
Immunoglobulin G as a glycoprotein.
Rademacher, T. W., Homans, S. W., Rb, P., & Dwek, R. A. (1986) · PubMed · Cited by 66
Enhancement of Complement Activation and Cytolysis of Human IgG3 by Deletion of Hinge Exons
Michaelsen, T. E., WESTBY, A. A. C., & Sandlie, I. (1990) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1990.tb03192.x · Cited by 63
Newman, R., Hariharan, K., Reff, M. E., Anderson, D. R., Braslawsky, G. R., Santoro, D. A., Hanna, N., Bugelski, P. J., Brigham-Burke, M. R., Crysler, C. S., et al. (2001) · Clinical Immunology · doi:10.1006/clim.2000.4975 · Cited by 63
Lund, J., Takahashi, N., Nakagawa, H., Goodall, M. D., Bentley, T., Hindley, S., Tyler, R., & Jefferis, R. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90145-2 · Cited by 62
Multiple binding sites on the CH2 domain of IgG for mouse FcγR11
Lund, J., Pound, J. D., Jones, P., Duncan, A., Bentley, T., Goodall, M. D., Levine, B. A., Jefferis, R., & Winte, G. (1992) · Molecular Immunology · doi:10.1016/0161-5890(92)90156-r · Cited by 59
Jain, A. K., Olsen, H. S., Vyzasatya, R., Burch, E. E., Sakoda, Y., Mérigeon, E. Y., Cai, L., Lu, C., Tan, M. T., Tamada, K., et al. (2012) · Arthritis Research & Therapy · doi:10.1186/ar4024 · Cited by 59
Glycosylation of Antibody Therapeutics: Optimisation for Purpose
Roy, J. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-407-0_13 · Cited by 59
Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats
Tawara, T., Hasegawa, K., Sugiura, Y., Harada, K., Miura, T., Hayashi, S., Tahara, T., Ishikawa, M., Yoshida, H., Kubo, K., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2294 · Cited by 56
Shen, L., Graziano, R. F., & Fanger, M. W. (1989) · Molecular Immunology · doi:10.1016/0161-5890(89)90114-4 · Cited by 54
Monnet, C., Jorieux, S., Souyris, N., Zaki, O., Jacquet, A., Fournier, N., Crozet, F., de Romeuf, C., Bouayadi, K., Urbain, R., et al. (2014) · mAbs · doi:10.4161/mabs.27854 · Cited by 54
Einarsdottir, H., Ji, Y., Visser, R., Mo, C., Luo, G., Scherjon, S. A., van der Schoot, C. E., & Vidarsson, G. (2013) · Transfusion · doi:10.1111/trf.12334 · Cited by 53
Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis
Thiruppathi, M., Sheng, J. R., Li, L., Prabhakar, B. S., & Meriggioli, M. N. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.12.014 · Cited by 48
Immunotherapy for Head and Neck Cancer
Sim, F. W., Leidner, R. S., & Bell, R. B. (2018) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2018.09.002 · Cited by 48
Mueller, J. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Squinto, S. P., Matis, L. A., & Evans, M. J. (1997) · Molecular Immunology · doi:10.1016/s0161-5890(97)00042-4 · Cited by 46
Natsume, A., Shimizu‐Yokoyama, Y., Satoh, M., Shitara, K., & Niwa, R. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01327.x · Cited by 45
Tam, S. H., McCarthy, S. G., Armstrong, A., Somani, S., Wu, S., Liu, X., Gervais, A., Ernst, R., Saro, D., Decker, R., et al. (2017) · Antibodies · doi:10.3390/antib6030012 · Cited by 43
Crystal structure of deglycosylated human IgG4-Fc
Davies, A. M., Jefferis, R., & Sutton, B. J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.05.015 · Cited by 39
Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications
Czajkowsky, D. M., Andersen, J. T., Fuchs, A., Wilson, T. J., Mekhaiel, D., Colonna, M., He, J., Shao, Z., Mitchell, D. A., Wu, G., et al. (2015) · Scientific Reports · doi:10.1038/srep09526 · Cited by 38
Niknami, M., Wang, M., Nguyen, T. D., & Pollard, J. D. (2013) · Journal of the Peripheral Nervous System · doi:10.1111/jns5.12022 · Cited by 37
Sensel, M. G., Kane, L. M., & Morrison, S. L. (1997) · Molecular Immunology · doi:10.1016/s0161-5890(97)00112-0 · Cited by 34
Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors
Derebe, M. G., Nanjunda, R. K., Gilliland, G. L., Lacy, E. R., & Chiu, M. L. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.02.006 · Cited by 33
Humanized, Nonmitogenic OKT3 Antibody, huOKT3γ(Ala-Ala): Initial Clinical Experience
Woodle, E. S., Bluestone, J. A., Zivin, R. A., Jolliffe, L. K., Auger, J., Xu, D., & Thistlethwaite, J. R. (1998) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)00278-4 · Cited by 32
Hybrid IgA2/IgG1 Antibodies with Tailor-Made Effector Functions
Chintalacharuvu, K. R., Vuong, L.-U. C., Loi, L. A., Larrick, J. W., & Morrison, S. L. (2001) · Clinical Immunology · doi:10.1006/clim.2001.5083 · Cited by 31
Immunotherapy for Head and Neck Cancer
Sim, F. W., Leidner, R. S., & Bell, R. B. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.006 · Cited by 31
Kang, T. H., Lee, C., Delidakis, G., Jung, J., Goff, O. R.-L., Lee, J., Kim, J. E., Charab, W., Bruhns, P., & Georgiou, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00562 · Cited by 31
Blundell, P. A., Le, N. P. L., Allen, J., Watanabe, Y., & Pleass, R. J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.795047 · Cited by 26
Fonseca, M. H. G., Furtado, G. P., Bezerra, M. R. L., Pontes, L. Q., & Fernandes, C. F. C. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.07.141 · Cited by 24
The immunoglobulin hinge (Interdomain) region
Adlersberg, J. B. (1976) · La Ricerca in Clinica e in Laboratorio · doi:10.1007/bf02899970 · Cited by 23
Shen, Y., Li, H., Zhao, L., Li, G., Chen, B., Guo, Q., Gao, B., Wu, J., Yang, T., Jin, L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183326 · Cited by 17
Nnane, I. P., Han, C., Jiao, Q., Tam, S. H., Davis, H. M., & Xu, Z. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12761 · Cited by 13
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Therapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R., & De Clercq, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 676
Winkler, E. S., Gilchuk, P., Yu, J., Bailey, A. L., Chen, R. E., Chong, Z., Zost, S. J., Jang, H., Huang, Y., Allen, J. D., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.026 · Cited by 366
Engineering protein-based therapeutics through structural and chemical design
Ebrahimi, S. B., & Samanta, D. (2023) · Nature Communications · doi:10.1038/s41467-023-38039-x · Cited by 382
Metadata
- Authors
- Saunders, K. O.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-06-07
- Volume
- 10
- Pages
- 1296-1296
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2969038446
- Cited by
- 316
- References
- 167
- FWCI
- 24.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.